The objective of this study was to identify possible biomarkers and to explore the mechanisms of suppression of vemurafenib on melanoma progression.
Methods
GSE42872 affymetrix microarray data were downloaded from the Gene Expression Omnibus database for further analysis. Differentially expressed genes (DEGs) between vehicle-treated samples and vemurafenibtreated samples were identified. Gene ontology and pathway enrichment analysis of DEGs were performed, followed by protein-protein interaction (PPI) network construction. Furthermore, the functional modules of the PPI network were screened using BioNet analysis tool. Finally, Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis was performed for DEGs in the module.
Results
In total, 794 upregulated transcripts corresponding to 214 genes and 977 downregulated transcripts corresponding to 325 genes were screened. The downregulated DEGs were significantly enriched in pathways such as cell cycle, DNA replication, and p53 signaling pathway. Upregulated DEGs were significantly enriched in phosphatidylinositol signaling system and inositol phosphate metabolism. Significantly enriched functions of downregulated DEGs were mitotic cell cycle, nuclear division, DNA metabolic process, cell cycle, and mitosis. Upregulated DEGs were mainly enriched in single multicellular organism process and multicellular organismal process. Moreover, cell division cycle 6, checkpoint kinase 1 (CHEK1), E2F transcription factor 1 (E2F1), epidermal growth factor receptor (EGFR), and phosphoinositide-3-kinase, regulatory subunit 1-α (PIK3R1) of the module were remarkably enriched in pathways such as cell cycle, apoptosis, focal adhesion, and DNA replication.
Conclusions
Cell division cycle 6, CHEK1, E2F1, EGFR, and PIK3R1 of the module and their relative pathways, cell cycle, and focal adhesion might play important roles of suppression of vemurafenib on melanoma progression.
TsaoH., ChinL., GarrawayL.A., FisherD.E.Melanoma: from mutations to medicine. Genes Dev.2012; 26(11): 1131–1155.
2.
MacKieR.M., HauschildA., EggermontA.M.Epidemiology of invasive cutaneous melanoma. Ann Oncol.2009; 20(Suppl 6): vi1–7.
3.
JemalA., BrayF., CenterM.M., FerlayJ., WardE., FormanD.Global cancer statistics. CA Cancer J Clin.2011; 61(2): 69–90.
4.
SibbrittT., PatelH.R., PreissT.Mapping and significance of the mRNA methylome. Wiley Interdiscip Rev RNA.2013; 4(4): 397–422.
5.
MillerA.J., MihmM.C.Jr.Melanoma. N Engl J Med.2006; 355(1): 51–65.
6.
ParmenterT.J., KleinschmidtM., KinrossK.M.Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov.2014; 4: 423–433.
7.
JaegerJ., KoczanD., ThiesenH.J.Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res.2007; 13: 806–815.
8.
ChapmanPBHA, HauschildA., RobertC.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med.2011; 364(26): 2507–2516.
9.
ChapmanP.B., HauschildA., RobertC.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med.2011; 364(26): 2507–2516.
10.
LukeJ.J., HodiF.S.Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma. Clin Cancer Res.2012; 18: 9–14.
11.
Gray-SchopferV., WellbrockC., MaraisR.Melanoma biology and new targeted therapy. Nature.2007; 445(7130): 851–857.
12.
HeidornS.J., MilagreC., WhittakerS.Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell.2010; 140(2): 209–221.
13.
PoulikakosP.I., ZhangC., BollagG., ShokatK.M., RosenN.RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature.2010; 464(7287): 427–430.
14.
VillanuevaJ., VulturA., LeeJ.T.Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell.2010; 18(6): 683–695.
15.
GautierL., CopeL., BolstadB.M., IrizarryR.A.affy: analysis of Affymetrix GeneChip data at the probe level. Bioinformatics.2004; 20(3): 307–315.
16.
IrizarryR.A., HobbsB., CollinF.Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics.2003; 4(2): 249–264.
17.
BenjamíniY., DraiD., ElmerG., KafkafiN., GolaniI.Controlling the false discovery rate in behavior genetics research. Behav Brain Res.2001; 125(1-2): 279–284.
18.
AshburnerM., BallC.A., BlakeJ.A.; The Gene Ontology Consortium. Gene ontology: tool for the unification of biology. Nat Genet.2000; 25(1): 25–29.
19.
KanehisaM., GotoS.KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res.2000; 28(1): 27–30.
20.
HuangW., ShermanB.T., LempickiR.A.Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc.2009; 4(1): 44–57.
21.
ZhaoM., SunJ., ZhaoZ.TSGene: a web resource for tumor suppressor genes. Nucleic Acids Res.2013; 41(Database issue): D970–D976.
22.
ChenJ.S., HungW.S., ChanH.H., TsaiS.J., SunH.S.In silico identification of oncogenic potential of fyn-related kinase in hepatocellular carcinoma. Bioinformatics.2013; 29(4): 420–427.
23.
SrihariS., LeongH.W.Temporal dynamics of protein complexes in PPI networks: a case study using yeast cell cycle dynamics. BMC Bioinformatics.2012; 13(Suppl 17): S16.
24.
FranceschiniA., SzklarczykD., FrankildS.STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res.2013; 41(Database issue): D808–D815.
25.
SmootM.E., OnoK., RuscheinskiJ., WangP.L., IdekerT.Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics.2011; 27(3): 431–432.
26.
BeisserD., KlauG.W., DandekarT., MüllerT., DittrichM.T.BioNet: an R-Package for the functional analysis of biological networks. Bioinformatics.2010; 26(8): 1129–1130.
UrregoD., TomczakA.P., ZahedF., StühmerW., PardoL.A.Potassium channels in cell cycle and cell proliferation. Philos Trans R Soc Lond B Biol Sci.2014; 369(1638): 20130094.
29.
CollerH.A.What's taking so long? S-phase entry from quiescence versus proliferation. Nat Rev Mol Cell Biol.2007; 8(8): 667–670.
30.
BlowJ.J., GillespieP.J.Replication licensing and cancer: a fatal entanglement?Nat Rev Cancer.2008; 8(10): 799–806.
31.
YanZ., DeGregoriJ., ShohetR., LeoneG., StillmanB., NevinsJ.R., WilliamsR.S.CDC6 is regulated by E2F and is essential for DNA replication in mammalian cells. Proc Natl Acad Sci USA.1998; 95(7): 3603–3608.
32.
KnudsenE.S., BuckmasterC., ChenT.T., FeramiscoJ.R., WangJ.Y.Inhibition of DNA synthesis by RB: effects on G1/S transition and S-phase progression. Genes Dev.1998; 12(15): 2278–2292.
33.
WalworthN.C.Cell-cycle checkpoint kinases: checking in on the cell cycle. Curr Opin Cell Biol.2000; 12(6): 697–704.
34.
ChenP., LuoC., DengY.The 1.7 A crystal structure of human cell cycle checkpoint kinase Chk1: implications for Chk1 regulation. Cell.2000; 100(6): 681–692.
35.
LiuQ., GuntukuS., CuiX.S.Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev.2000; 14(12): 1448–1459.
36.
LuoY L.J.New opportunities in chemosensitization and radiosensitization: modulating the DNA-damage response. Future Drugs.2005; 5: 333–342.
37.
VerlindenL., Vanden BemptI., EelenG.The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor/progesterone receptor/HER-2 breast carcinomas. Cancer Res.2007; 67(14): 6574–6581.
38.
EastmanA., KohnE.A., BrownM.K.A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity: similarities and differences to the cell cycle checkpoint abrogator UCN-01. Mol Cancer Ther.2002; 1(12): 1067–1078.
39.
TseA.N., RendahlK.G., SheikhT.CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Clin Cancer Res.2007; 13: 591–602.
40.
LuoM., GuanJ.L.Focal adhesion kinase: a prominent determinant in breast cancer initiation, progression and metastasis. Cancer Lett.2010; 289(2): 127–139.
41.
ParsonsJ.T., MartinK.H., SlackJ.K., TaylorJ.M., WeedS.A.Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. Oncogene.2000; 19(49): 5606–5613.
42.
LongW., YiP., AmazitL.SRC-3Delta4 mediates the interaction of EGFR with FAK to promote cell migration. Mol Cell.2010; 37(3): 321–332.
43.
Diaz-BenjumeaF.J., HafenE.The sevenless signalling cassette mediates Drosophila EGF receptor function during epidermal development. Development.1994; 120(3): 569–578.
44.
CiardielloF., TortoraG.A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res.2001; 7: 2958–2970.
45.
CorcoranR.B., EbiH., TurkeA.B.EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov.2012; 2: 227–235.
46.
ShekarS.C., WuH., FuZ.Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit. J Biol Chem.2005; 280(30): 27850–27855.
47.
SamuelsY., DiazL.A.Jr., Schmidt-KittlerO.Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell.2005; 7(6): 561–573.
48.
JiménezC., PortelaR.A., MelladoM.Role of the PI3K regulatory subunit in the control of actin organization and cell migration. J Cell Biol.2000; 151(2): 249–262.
49.
LuoJ., ManningB.D., CantleyL.C.Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell.2003; 4(4): 257–262.
50.
TaniguchiC.M., WinnayJ., KondoT.The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling. Cancer Res.2010; 70(13): 5305–5315.
51.
CizkovaM., VacherS., MeseureD.PIK3R1 underexpression is an independent prognostic marker in breast cancer. BMC Cancer.2013; 13(1): 545.
